Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 265

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study

Open access
Van Cutsem, Eric, di Bartolomeo, Maria, Smyth, Elizabeth, Chau, Ian, Park, Haeseong, Siena, Salvatore, Lonardi, Sara, Wainberg, Zev A, Ajani, Jaffer, Chao, Joseph, Janjigian, Yelena, Qin, Amy, Singh, Jasmeet, Barlaskar, Ferdous, Kawaguchi, Yoshinori, Ku, Geoffrey·2023·The Lancet Oncology

Abstract

Background Approximately 15‒20% of advanced gastric and gastroesophageal junction (GEJ) cancers overexpress HER2. In DESTINY-Gastric01, the HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) improved response and overall survival (OS) versus chemotherapy in patients from Japan and Korea with locally advanced and/or metastatic HER2-positive gastric or GEJ cancer whose disease progressed after two lines of therapy including trastuzumab. Here, we report data from the single-arm, phase 2 DESTINY-Gastric02 trial, which examines T-DXd in Western patients. Methods DESTINY-Gastric02 is a multicentre, single-arm study in adult patients from the United States and Europe. Eligible patients were aged ≥18 years, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had pathologically documented unresectable or metastatic gastric/GEJ cancer, had progressive disease on or after first-line therapy with a trastuzumab regimen, and had centrally confirmed HER2-positive disease on a postprogression biopsy. Patients received 6·4 mg/kg of T-DXd intravenously every 3 weeks until disease progression, withdrawal by patient, physician decision, or death. The primary endpoint was confirmed objective response rate by independent central review (ICR) which was assessed in the full analysis set. Safety was assessed in the safety analysis set. This ongoing trial is registered with ClinicalTrials.gov, NCT04014075. Findings Between November 26, 2019, and November 8, 2021, 79 patients were treated with T-DXd (57 male, 22 female), with a median follow-up of 10·2 months (IQR 5·6‒12·9 months). A confirmed objective response was reported in 33 patients (41·8% [95% CI 30·8‒53·4]), as assessed by ICR. The most common grade ≥3 treatment-emergent adverse events (TEAEs) occurring in ≥5% of patients were anaemia (n=11; 13·9%), nausea (n=6; 7·6%), neutrophil count decrease (n=6; 7·6%), and white blood cell decrease (n=5; 6·3%). Drug-related serious TEAEs occurred in 10 patients (12·7%). Drug-related TEAEs associated with the outcome of death occurred in 2 patients (2·5%) and were due to interstitial lung disease/pneumonitis. Eight patients (10·1%) had adjudicated drug-related interstitial lung disease/pneumonitis (two grade 1 [2·5%], four grade 2 [5·1%], and two grade 5 [2·5%]). Interpretation These clinically meaningful results, demonstrated by the robust ORR, prolonged PFS and OS, and tolerable safety profile, support the use of T-DXd as second-line therapy in patients with HER2-positive advanced gastric/GEJ cancer. Funding Daiichi Sankyo

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(23)00215-2

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 265

Metadata

Authors
Van Cutsem, E., di Bartolomeo, M., Smyth, E., Chau, I., Park, H., Siena, S., Lonardi, S., Wainberg, Z. A., Ajani, J., Chao, J., Janjigian, Y., Qin, A., Singh, J., Barlaskar, F., Kawaguchi, Y., & Ku, G.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2023-07
Volume
24
Issue
7
Pages
744-756
ISSN
1470-2045 (ISSN-L)
OpenAlex
W4380738795
Cited by
265
References
21
FWCI
41.62
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(23)00215-2
The paper
Van Cutsem, E., di Bartolomeo, M., Smyth, E., Chau, I., Park, H., Siena, S., Lonardi, S., Wainberg, Z. A., Ajani, J., Chao, J., Janjigian, Y., Qin, A., Singh, J., Barlaskar, F., Kawaguchi, Y., & Ku, G. (2023). Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(23)00215-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.